Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: A remission induction therapy for aggressive pediatric post-transplant lymphoproliferative disease (PTLD)

Pediatric Blood and Cancer

Volumn 57, Issue 2, 2011, Pages 324-328

  Giraldi, Eugenia ^a   Provenzi, Massimo ^a   Fiocchi, Roberto ^a   Colledan, Michele ^a   Cornelli, Pieremilio ^a   Torre, Giuliano ^a,b   Rambaldi, Alessandro ^a   Conter, Valentino ^a  

^a OSPEDALI RIUNITI   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Children; Fludarabine based therapy; PTLD; Rituximab; Solid organ transplantation; Treatment

Indexed keywords

AZATHIOPRINE; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; RITUXIMAB; TACROLIMUS; VINCRISTINE; VINDESINE;

ARTICLE; ASCITES; B LYMPHOCYTE; BILE DUCT ATRESIA; CARDIAC GRAFT REJECTION; CARDIOMYOPATHY; CASE REPORT; CD3+ T LYMPHOCYTE; CHILD; COMBINATION CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GRAFT REJECTION; HEART EJECTION FRACTION; HEART RIGHT VENTRICLE FAILURE; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LYMPHOCYTE COUNT; LYMPHOPROLIFERATIVE DISEASE; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PLEURA EFFUSION; PNEUMOCYSTIS JIROVECI; PNEUMONIA; POSTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; REMISSION; STEROID THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; REMISSION INDUCTION; VIDARABINE;

EID: 79958858376     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23004     Document Type: Article

References (20)

1. Dotti G, Fiocchi R, Motta T, et al. Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation 2000; 69: 827-833.
2. Dotti G, Fiocchi R, Motta T, et al. Lymphomas occurring late after solid-organ transplantation: Influence of treatment on the clinical outcome. Transplantation 2002; 74: 1095-1102.
3. Leblond V, Dhedin N, Mamzer Bruneel MF, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001; 19: 772-778.
4. Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006; 6: 569-576.
5. Dotti G, Rambaldi A, Fiocchi R, et al. Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ transplant. Haematologica 2001; 86: 618-623.
6. Comoli P, Maccario R, Locatelli F, et al. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Am J Transplant 2005; 5: 1415-1422.
7. Schubert S, Abdul-Khaliq H, Lehmkuhl HB, et al. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients. Pediatr Transplant 2009; 13: 54-62.
8. Trappe R, Hinrichs C, Appel U, et al. Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression. Am J Transplant 2009; 9: 2331-2337.
9. Choquet S, Oertel S, LeBlond V, et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: Proceed with caution. Ann Hematol 2007; 86: 599-607.
10. Dharnidharka VR, Gupta S. PTLD treatment: Reducing the chemotherapy burden through addition of rituximab. Pediatr Transplant 14: 10-11.
11. Windebank K, Walwyn T, Kirk R, et al. Post cardiac transplantation lymphoproliferative disorder presenting as t(8;14) Burkitt leukaemia/lymphoma treated with low intensity chemotherapy and rituximab. Pediatr Blood Cancer 2009; 53: 392-396.
12. Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001; 114: 800-809.
13. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064-3071.
14. Bosch F, Abrisqueta P, Villamor N, et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: A new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol 2009; 27: 4578-4584.
15. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995; 13: 2431-2448.
16. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813-1826.
17. Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: Dissimilarities from lymphomas in adults. Semin Oncol 1980; 7: 332-339.
18. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: Summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997; 14: 8-14.
19. Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood 1999; 94: 3294-3306.
20. Ohta H, Fukushima N, Ozono K. Pediatric post-transplant lymphoproliferative disorder after cardiac transplantation. Int J Hematol 2009; 90: 127-136.